首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 85 % SDS-PAGE |
| 种属 | Human |
| 靶点 | CCL20 |
| Uniprot No | P78556 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-95aa |
| 氨基酸序列 | ASNFDCCLGYTDRILHPKFIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKN |
| 预测分子量 | 39.4Da |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"CCL20 and β-defensin2 synergize for neutrophil recruitment in Crohn’s disease"** -作者：Kobayashi 等，*Journal of Immunology* (2019)
摘要：研究揭示了重组CCL20蛋白与β-防御素2协同促进中性粒细胞向肠道炎症部位迁移的机制，为克罗恩病的免疫治疗提供新靶点。
2. **"Recombinant CCL20 enhances CD8+ T cell infiltration in colorectal cancer models"** -作者：Liu 等，*Cancer Research* (2020)
摘要：通过动物模型证明，局部注射重组CCL20蛋白可显著增加肿瘤微环境中效应T细胞的浸润，抑制结直肠癌进展并提高化疗响应率。
3. **"Structural basis of CCL20 recognition by its receptor CCR6"** -作者：Smith 等，*Nature Communications* (2021)
摘要：利用X射线晶体学解析重组CCL20蛋白与CCR6受体的复合物结构，阐明了其特异性结合的分子机制，为设计靶向药物奠定基础。
4. **"CCL20 as a mucosal adjuvant in recombinant vaccines"** -作者：Zhang 等，*Frontiers in Immunology* (2018)
摘要：研究发现重组CCL20蛋白作为佐剂可增强呼吸道疫苗的黏膜免疫应答，通过招募树突状细胞和淋巴细胞提升抗原呈递效率。
CCL20 (Chemokine (C-C motif) ligand 20), also known as macrophage inflammatory protein-3α (MIP-3α) or liver-activated regulated chemokine (LARC), is a small cytokine belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting lymphocytes, dendritic cells, and other immune cells to sites of inflammation or infection through its interaction with the chemokine receptor CCR6. This receptor-ligand pair is particularly vital in mucosal immunity, facilitating the homing of CCR6-expressing cells like Th17 cells and regulatory T cells to epithelial tissues.
Recombinant CCL20 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce a purified, bioactive form of the chemokine. It typically retains the native structure and function, enabling researchers to study its role in inflammatory diseases, autoimmune disorders, and cancer. For instance, CCL20 is implicated in pathologies such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease due to its overexpression in affected tissues. In cancer, it exhibits dual roles—either promoting tumor progression by recruiting immunosuppressive cells or enhancing anti-tumor immunity depending on the microenvironment.
The recombinant protein is widely used in *in vitro* and *in vivo* studies to investigate immune cell migration, signaling pathways, and therapeutic targeting. Its production involves stringent quality controls (e.g., SDS-PAGE, endotoxin testing) to ensure batch consistency and biological activity, often verified via chemotaxis assays. As a research tool, recombinant CCL20 aids in unraveling disease mechanisms and developing CCR6/CCL20 axis inhibitors or agonists for potential clinical applications.
×
